Literature DB >> 1418293

Analysis of anti-idiotypic antibodies against anti-microsomal antibodies in patients with thyroid autoimmunity.

N Tandon1, D R Jayne, A M McGregor, A P Weetman.   

Abstract

Anti-microsomal antibody (AMA) activity was inhibited in 14 of 16 sera and in all 12 IgG preparations from patients with postpartum thyroiditis following incubation with F(ab')2 fragments from normal polyspecific immunoglobulin for therapeutic use (ivIg). Similar results were observed with sera from seven of seven patients with Graves' disease and five of six patients with autoimmune hypothyroidism. Results of these competitive binding assays and affinity chromatography of AMA IgG on Sepharose-bound F(ab'), fragments from ivIg indicated that AMA antibodies reacted with ivIg through idiotypic-anti-idiotypic interactions. Eight out of 10 IgG preparations from patients with autoimmune thyroid disease also showed inhibition of AMA activity when coincubated with autologous IgM at various IgG:IgM molar ratios. These observations suggest that ivIg can inhibit anti-microsomal antibodies through idiotype-anti-idiotype interactions and that such interactions occur with IgM anti-idiotype antibodies in vivo, providing evidence of a role for idiotypic network regulation in the control of thyroid autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1418293     DOI: 10.1016/0896-8411(92)90153-h

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  11 in total

1.  Neutrophil priming by cigarette smoke condensate and a tobacco anti-idiotypic antibody.

Authors:  S M Koethe; J R Kuhnmuench; C G Becker
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

Review 2.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 3.  Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Authors:  Christiane S Hampe
Journal:  Autoimmunity       Date:  2012-02-23       Impact factor: 2.815

Review 4.  Toward molecular targeting with specific intravenous immunoglobulin preparation.

Authors:  Miri Blank; Israel Nur; Orgad Toub; Anabel Maor; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 5.  Intravenous immunoglobulin for treatment of pemphigus.

Authors:  Lehavit Akerman; Daniel Mimouni; Michael David
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

6.  Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults.

Authors:  Z J Pan; C J Anderson; H A Stafford
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

7.  Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; L Ashkenazi; Y Milner; M Frusic-Zlotkin; G J Anhalt; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

8.  Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; A S Payne; G J Anhalt; C Avivi; I Barshack; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2010-10-21       Impact factor: 4.330

9.  Antiidiotype antibody against platelet anti-GPIIIa contributes to the regulation of thrombocytopenia in HIV-1-ITP patients.

Authors:  M Nardi; S Karpatkin
Journal:  J Exp Med       Date:  2000-06-19       Impact factor: 14.307

Review 10.  Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.

Authors:  Melvin Berger; Daniel E McCallus; Cindy Shin-Yi Lin
Journal:  J Peripher Nerv Syst       Date:  2013-12       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.